Novel Lipid Nanoparticle Delivery Reagent And Rapid Manufacturing Workflow To Accelerate Preclinical Development Of RNA Vaccines

The biggest vaccine campaign in history is ongoing against COVID-19, with RNA vaccines playing a key role. Due to the rapid degradation of RNA and low cellular uptake, an essential element of RNA vaccines are lipid nanoparticle (LNP) delivery systems. Limited access to ionizable lipids and LNP compositions, and the difficulty in scale-up production of RNA-LNPs remain challenges in the field. In this study, we aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.